Skip to main content
. 2019 Oct 31;20(21):5447. doi: 10.3390/ijms20215447

Figure 3.

Figure 3

Potential molecular predictive factors for immunotherapy or target therapy in conjunctival melanoma. (A) NF1 (17q11.2) mutations, which cause the loss of RAS-bound GTP hydrolysis, are associated with high mutational load and could help to predict the efficacy of immunotherapy; (B) High levels of AKT, phosphorylated S6 and 4E-BP1 are related to mTOR mutation and could predict the efficacy of PI3K/AKT/mTOR inhibition therapy.